Lipocine Inc. Files 8-K Report

Ticker: LPCN · Form: 8-K · Filed: 2025-03-12T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, filing, financial-update

TL;DR

Lipocine filed an 8-K on March 12, 2025, covering other events and financial exhibits.

AI Summary

On March 12, 2025, Lipocine Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing signals to investors and the market that Lipocine Inc. is providing updated information, which could include significant operational or financial developments.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate disclosure of negative events or significant financial changes, suggesting a routine update.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Lipocine Inc.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events.

When was this 8-K report filed?

The report was filed on March 12, 2025.

What is Lipocine Inc.'s principal executive office address?

The principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the Commission File Number for Lipocine Inc.?

The Commission File Number is 001-36357.

Does the filing mention any specific new material events or financial figures?

The provided excerpt of the filing does not detail specific new material events or financial figures.

From the Filing

0001493152-25-009955.txt : 20250312 0001493152-25-009955.hdr.sgml : 20250312 20250312093512 ACCESSION NUMBER: 0001493152-25-009955 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250312 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250312 DATE AS OF CHANGE: 20250312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 25730255 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2025-03-12 2025-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): March 12, 2025     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   On March 12, 2025, the Company issued a press release announcing that the FDA has recently informed sponsors of approved testosterone products about class-wide labeling changes. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description       99.1   Lipocine Announces FDA Labeling Changes for Testo

View on Read The Filing